Cerliponase alfa ▼ is not registered in all countries, and where it is registered the content of its indication along with other content may vary.
Please refer to your local prescribing information before prescribing cerliponase alfa.
▼ This medicinal product is subject to additional monitoring, special reporting is required in relation to adverse reactions. Email us at medinfo@bmrn.com for further details.
This website has been developed as a scientific and educational resource for healthcare professionals, dedicated to advancing knowledge, collaboration and clinical excellence in CLN2 disease.
Explore the latest research, resources, and expert insights to support better care for patients affected by neuronal ceroid lipofuscinosis. This website may contain promotional material on BioMarin products.
Please be aware that marketing authorization for BioMarin products may vary from country to country, and where products are registered, they might have different labels as approved by the local regulatory agencies. Please consult with BioMarin Medical Information for more information and or Prescribing Information provided above.
Get access to the latest developments in CLN2. Register today and sign-up to receive updates
Resource
Featured
Prof Schulz reviews the challenges and benefits of long-term treatment with cerliponase alfa, management of atypical CLN2 phenotypes, and the role of newborn screening in achieving early, ideally pre-symptomatic intervention in CLN2 disease.
Resource
Featured
We are pleased to share with you our booklet “Genetics and Genomics: Applications to Medicine and Health”.
Resource
Featured
Share best practices, align care standards, and optimise patient pathways while fostering thought leadership and advancing rare disease education and care.